What Procurement Teams Should Actually Be Evaluating In A Fill/Finish CDMO Request For Proposal (RFP)

Price and capacity are easy to compare in a fill/finish RFP, but they rarely tell the full story. Strong procurement decisions come from understanding assumptions, risk, and how a CDMO behaves when conditions change. This piece breaks down the evaluation areas most likely to affect timelines and total cost, including overlooked testing scope, stability work, and method transfer. It explores why tech transfer exposes the true strength of a partner, from how scalability risks are assessed to how unknown molecule attributes are handled. The discussion also reframes “capacity” by examining real constraints across labs, engineering, and project management—not just open line time. Quality culture, escalation paths, and continuity from early clinical work through commercial launch are treated as measurable factors, not soft impressions. For procurement teams looking to ask better questions and avoid mid‑program surprises, this framework offers a clearer way to identify partners built for long‑term success.